BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

Bristol-Myers Squibb Company's Revenue by Segment

In fiscal year 2025, Bristol-Myers Squibb Company's revenue by segment (products & services) are as follows:

  • Abecma: $427.00 M
  • Abraxane: $368.00 M
  • Breyanzi: $1.36 B
  • Camzyos: $1.07 B
  • Cobenfy: $155.00 M
  • Eliquis: $14.44 B
  • Krazati: $205.00 M
  • Opdivo: $10.05 B
  • Opdivo Ovantig: $238.00 M
  • Opdualag: $1.19 B
  • Orencia: $3.71 B
  • Other Growth Brands: $1.92 B
  • Other Legacy Brands: $798.00 M
  • Pomalyst/Imnovid: $2.73 B
  • Reblozyl: $2.33 B
  • Revlimid: $2.95 B
  • Sotyktu: $291.00 M
  • Sprycel: $493.00 M
  • Yervoy: $2.90 B
  • Zeposia: $577.00 M

Learn more about Bristol-Myers Squibb Company’s Revenue by Geography

Check out competitors to Bristol-Myers Squibb Company in a side-by-side comparison.

Explore additional financial metrics for Bristol-Myers Squibb Company.

Continue reading...

The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

In fiscal year 2023, Bristol-Myers Squibb Company's revenue by segment is as follows:

  • Abecma generated $472.00 M in revenue, representing 1.1% of its total revenue.
  • Abraxane generated $1.00 B in revenue, representing 2.34% of its total revenue.
  • Breyanzi generated $364.00 M in revenue, representing 0.85% of its total revenue.
  • Camzyos generated $231.00 M in revenue, representing 0.54% of its total revenue.
  • Eliquis generated $12.21 B in revenue, representing 28.5% of its total revenue.
  • Opdivo generated $9.01 B in revenue, representing 21.03% of its total revenue.
  • Opdualag generated $627.00 M in revenue, representing 1.46% of its total revenue.
  • Orencia generated $3.60 B in revenue, representing 8.41% of its total revenue.
  • Pomalyst/Imnovid generated $3.44 B in revenue, representing 8.03% of its total revenue.
  • Reblozyl generated $1.01 B in revenue, representing 2.35% of its total revenue.
  • Revlimid generated $6.10 B in revenue, representing 14.23% of its total revenue.
  • Sotyktu generated $170.00 M in revenue, representing 0.4% of its total revenue.
  • Sprycel generated $1.93 B in revenue, representing 4.51% of its total revenue.
  • Yervoy generated $2.24 B in revenue, representing 5.23% of its total revenue.
  • Zeposia generated $434.00 M in revenue, representing 1.01% of its total revenue.

The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 28.5% of its total revenue.
The smallest segment for Bristol-Myers Squibb Company is the Sotyktu, which represents 0.4% of its total revenue.

The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

In fiscal year 2024, Bristol-Myers Squibb Company's revenue by segment is as follows:

  • Abecma generated $406.00 M in revenue, representing 0.84% of its total revenue.
  • Abraxane generated $875.00 M in revenue, representing 1.81% of its total revenue.
  • Breyanzi generated $747.00 M in revenue, representing 1.55% of its total revenue.
  • Camzyos generated $602.00 M in revenue, representing 1.25% of its total revenue.
  • Cobenfy generated $10.00 M in revenue, representing 0.02% of its total revenue.
  • Eliquis generated $13.33 B in revenue, representing 27.63% of its total revenue.
  • Krazati generated $126.00 M in revenue, representing 0.26% of its total revenue.
  • Opdivo generated $9.30 B in revenue, representing 19.28% of its total revenue.
  • Opdualag generated $928.00 M in revenue, representing 1.92% of its total revenue.
  • Orencia generated $3.68 B in revenue, representing 7.63% of its total revenue.
  • Other Growth Brands generated $1.61 B in revenue, representing 3.33% of its total revenue.
  • Other Legacy Brands generated $925.00 M in revenue, representing 1.92% of its total revenue.
  • Pomalyst/Imnovid generated $3.55 B in revenue, representing 7.35% of its total revenue.
  • Reblozyl generated $1.77 B in revenue, representing 3.67% of its total revenue.
  • Revlimid generated $5.77 B in revenue, representing 11.96% of its total revenue.
  • Sotyktu generated $246.00 M in revenue, representing 0.51% of its total revenue.
  • Sprycel generated $1.29 B in revenue, representing 2.66% of its total revenue.
  • Yervoy generated $2.53 B in revenue, representing 5.24% of its total revenue.
  • Zeposia generated $566.00 M in revenue, representing 1.17% of its total revenue.

The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 27.63% of its total revenue.
The smallest segment for Bristol-Myers Squibb Company is the Cobenfy, which represents 0.02% of its total revenue.

The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

In fiscal year 2025, Bristol-Myers Squibb Company's revenue by segment is as follows:

  • Abecma generated $427.00 M in revenue, representing 0.89% of its total revenue.
  • Abraxane generated $368.00 M in revenue, representing 0.76% of its total revenue.
  • Breyanzi generated $1.36 B in revenue, representing 2.82% of its total revenue.
  • Camzyos generated $1.07 B in revenue, representing 2.22% of its total revenue.
  • Cobenfy generated $155.00 M in revenue, representing 0.32% of its total revenue.
  • Eliquis generated $14.44 B in revenue, representing 29.97% of its total revenue.
  • Krazati generated $205.00 M in revenue, representing 0.43% of its total revenue.
  • Opdivo generated $10.05 B in revenue, representing 20.85% of its total revenue.
  • Opdivo Ovantig generated $238.00 M in revenue, representing 0.49% of its total revenue.
  • Opdualag generated $1.19 B in revenue, representing 2.46% of its total revenue.
  • Orencia generated $3.71 B in revenue, representing 7.69% of its total revenue.
  • Other Growth Brands generated $1.92 B in revenue, representing 3.99% of its total revenue.
  • Other Legacy Brands generated $798.00 M in revenue, representing 1.66% of its total revenue.
  • Pomalyst/Imnovid generated $2.73 B in revenue, representing 5.67% of its total revenue.
  • Reblozyl generated $2.33 B in revenue, representing 4.83% of its total revenue.
  • Revlimid generated $2.95 B in revenue, representing 6.12% of its total revenue.
  • Sotyktu generated $291.00 M in revenue, representing 0.6% of its total revenue.
  • Sprycel generated $493.00 M in revenue, representing 1.02% of its total revenue.
  • Yervoy generated $2.90 B in revenue, representing 6.02% of its total revenue.
  • Zeposia generated $577.00 M in revenue, representing 1.2% of its total revenue.

The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 29.97% of its total revenue.
The smallest segment for Bristol-Myers Squibb Company is the Cobenfy, which represents 0.32% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2023 2024 2025
Sprycel 4.51% 2.66% 1.02%
Sotyktu 0.4% 0.51% 0.6%
Revlimid 14.23% 11.96% 6.12%
Reblozyl 2.35% 3.67% 4.83%
Pomalyst/Imnovid 8.03% 7.35% 5.67%
Orencia 8.41% 7.63% 7.69%
Opdualag 1.46% 1.92% 2.46%
Opdivo 21.03% 19.28% 20.85%
Eliquis 28.5% 27.63% 29.97%
Camzyos 0.54% 1.25% 2.22%
Breyanzi 0.85% 1.55% 2.82%
Abraxane 2.34% 1.81% 0.76%
Abecma 1.1% 0.84% 0.89%
Yervoy 5.23% 5.24% 6.02%
Zeposia 1.01% 1.17% 1.2%
Cobenfy - 0.02% 0.32%
Krazati - 0.26% 0.43%
Other Growth Brands - 3.33% 3.99%
Other Legacy Brands - 1.92% 1.66%
Opdivo Ovantig - - 0.49%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of Bristol-Myers Squibb Company.

In fiscal year 2025, the Eliquis generated the most revenue ($14.44 B), and the Cobenfy generated the least revenue ($155.00 M).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Abecma revenue increased 5.17% ($21.00 M) from $406.00 M (in 2024) to $427.00 M (in 2025).
  • Abraxane revenue decreased -57.94% ($507.00 M) from $875.00 M (in 2024) to $368.00 M (in 2025).
  • Breyanzi revenue increased 81.79% ($611.00 M) from $747.00 M (in 2024) to $1.36 B (in 2025).
  • Camzyos revenue increased 77.41% ($466.00 M) from $602.00 M (in 2024) to $1.07 B (in 2025).
  • Cobenfy revenue increased 1% ($145.00 M) from $10.00 M (in 2024) to $155.00 M (in 2025).
  • Eliquis revenue increased 8.33% ($1.11 B) from $13.33 B (in 2024) to $14.44 B (in 2025).
  • Krazati revenue increased 62.7% ($79.00 M) from $126.00 M (in 2024) to $205.00 M (in 2025).
  • Opdivo revenue increased 8.01% ($745.00 M) from $9.30 B (in 2024) to $10.05 B (in 2025).
  • Opdivo Ovantig revenue increased 100% ($238.00 M) from $0.00 (in 2024) to $238.00 M (in 2025).
  • Opdualag revenue increased 27.69% ($257.00 M) from $928.00 M (in 2024) to $1.19 B (in 2025).
  • Orencia revenue increased 0.62% ($23.00 M) from $3.68 B (in 2024) to $3.71 B (in 2025).
  • Other Growth Brands revenue increased 19.88% ($319.00 M) from $1.61 B (in 2024) to $1.92 B (in 2025).
  • Other Legacy Brands revenue decreased -13.73% ($127.00 M) from $925.00 M (in 2024) to $798.00 M (in 2025).
  • Pomalyst/Imnovid revenue decreased -22.91% ($812.00 M) from $3.55 B (in 2024) to $2.73 B (in 2025).
  • Reblozyl revenue increased 31.25% ($554.00 M) from $1.77 B (in 2024) to $2.33 B (in 2025).
  • Revlimid revenue decreased -48.88% ($2.82 B) from $5.77 B (in 2024) to $2.95 B (in 2025).
  • Sotyktu revenue increased 18.29% ($45.00 M) from $246.00 M (in 2024) to $291.00 M (in 2025).
  • Sprycel revenue decreased -61.66% ($793.00 M) from $1.29 B (in 2024) to $493.00 M (in 2025).
  • Yervoy revenue increased 14.62% ($370.00 M) from $2.53 B (in 2024) to $2.90 B (in 2025).
  • Zeposia revenue increased 1.94% ($11.00 M) from $566.00 M (in 2024) to $577.00 M (in 2025).
    • Continue reading...

    Summary Table

    Products & Services 2023
    Value Change
    		2024
    Value Change
    		2025
    Value Change
    Abecma $472.00 M - $406.00 M
    13.98%
    		$427.00 M
    5.17%
    Abraxane $1.00 B - $875.00 M
    12.85%
    		$368.00 M
    57.94%
    Breyanzi $364.00 M - $747.00 M
    105.22%
    		$1.36 B
    81.79%
    Camzyos $231.00 M - $602.00 M
    160.61%
    		$1.07 B
    77.41%
    Cobenfy - - $10.00 M - $155.00 M
    1,450.00%
    Eliquis $12.21 B - $13.33 B
    9.23%
    		$14.44 B
    8.33%
    Krazati - - $126.00 M - $205.00 M
    62.70%
    Opdivo $9.01 B - $9.30 B
    3.27%
    		$10.05 B
    8.01%
    Opdivo Ovantig - - - - $238.00 M -
    Opdualag $627.00 M - $928.00 M
    48.01%
    		$1.19 B
    27.69%
    Orencia $3.60 B - $3.68 B
    2.25%
    		$3.71 B
    0.62%
    Other Growth Brands - - $1.61 B - $1.92 B
    19.88%
    Other Legacy Brands - - $925.00 M - $798.00 M
    13.73%
    Pomalyst/Imnovid $3.44 B - $3.55 B
    3.02%
    		$2.73 B
    22.91%
    Reblozyl $1.01 B - $1.77 B
    75.89%
    		$2.33 B
    31.25%
    Revlimid $6.10 B - $5.77 B
    5.31%
    		$2.95 B
    48.88%
    Sotyktu $170.00 M - $246.00 M
    44.71%
    		$291.00 M
    18.29%
    Sprycel $1.93 B - $1.29 B
    33.37%
    		$493.00 M
    61.66%
    Yervoy $2.24 B - $2.53 B
    13.05%
    		$2.90 B
    14.62%
    Zeposia $434.00 M - $566.00 M
    30.41%
    		$577.00 M
    1.94%
    Total Revenue $42.83 B - $48.26 B
    12.68%
    		$48.20 B
    0.14%

    Frequently Asked Questions

    What was Bristol-Myers Squibb Company's largest product segment last year?

    In fiscal year 2025, Eliquis revenue reached $14.44 Billion, representing 29.97% of Bristol-Myers Squibb Company's total revenue and making it the largest segment for the company.

    Which product segment experienced the highest growth for Bristol-Myers Squibb Company last year?

    The Cobenfy segment is Bristol-Myers Squibb Company's highest growth segment, with a revenue growth of +1450% in 2025 compared to 2024.

    Related company

    Revenue Ranking

    Revenue Ranking

    Related

    Submit feedback to Bullfincher